Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Coronary Atherosclerosis: later-stage trial registry
2 of 6 indexed Coronary Atherosclerosis trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Coronary Atherosclerosis: 6 US clinical trials tracked, 2 recruiting.
Coronary Atherosclerosis is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, running 1 of these trials.
Enrollment posture brief
Registry condition coronary-atherosclerosis
OPEN 2 | RECR 33% | LATE 2 | EARLY 0 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Coronary Atherosclerosis lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Coronary Atherosclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Coronary Atherosclerosis is recruiting below its size-band peers.
2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Coronary Atherosclerosis research.
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Coronary Atherosclerosis enrolment sits around 263 participants.
Median target enrolment is 263 among the 6 trials that report a genuine target (sentinel values excluded). 1 of those (16.7%) plan for fewer than 100 participants.
-
Coronary Atherosclerosis splits between interventional and observational designs.
4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Using CTA Measures to Define Cardiac Risk In NFL Alumni
HeartFlow
NCT06831409
Coronary Atherosclerosis T1-Weighted Characterization (CATCH)
Cedars-Sinai Medical Center
NCT03504956
STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)
Sanofi
NCT00124332
Subclinical Atherosclerosis in HIV-infected Patients
Massachusetts General Hospital
NCT00455793
Coronary Atherosclerosis Evaluation by Arterial Wall Magnetic Resonance Imaging (MRI)
Johns Hopkins University
NCT00353795
Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
NCT00860847
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Coronary Atherosclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Coronary Atherosclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Coronary Atherosclerosis page
6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Coronary Atherosclerosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center sponsors the most Coronary Atherosclerosis trials on record, review their full trial history before evaluating a specific study. See Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Coronary Atherosclerosis condition card totals 6 registered trials; most-linked intervention Rimonabant (SR141716); top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.